RxDoctor Payments Data

Mary Kovacik Eicher, MD

Neurology · Greensburg, PANPI 1659799476

Payments from drug & device makers

$66,891in general payments, 2019–2025

Across 174 payments — averaging $384.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$65K
  • Eisai Inc.$468
  • Acadia Pharmaceuticals Inc$307
  • Pfizer$123
  • Ipsen Biopharmaceuticals, Inc$113
  • Vanda Pharmaceuticals Inc.$96
  • plus $506 from 12 others

What the payments were for

  • Speaking & faculty fees$60,77591%
  • Travel & lodging$2,0713%
  • Food & beverage$4,0446%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,891 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$164,976
Medicare patients
501
Services billed
6,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5022$1,020,430
Gamunex-CImmune Globul G/Gly/Iga Avg 4663$414,226
BotoxOnabotulinumtoxina240$382,772
QuliptaAtogepant27$28,001
Emgality PenGalcanezumab-Gnlm23$20,535
XeominIncobotulinumtoxina11$10,590
Tegretol XrCarbamazepine25$9,140
Aimovig AutoinjectorErenumab-Aooe11$8,163
Carbidopa-LevodopaCarbidopa/Levodopa101$5,319
Lacosamide32$5,053
Gabapentin148$3,533
Levetiracetam99$3,092
AmantadineAmantadine Hcl29$2,426
Pregabalin52$1,768
Pyridostigmine Bromide28$1,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta$65,277$410,773267 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$39$2,35841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →